Glenmark Pharma launches nasal spray for COVID-19 treatment in India
Glenmark Pharmaceuticals in partnership with SaNOtize Research has launched nasal spray for treating Covid-19.
On Wednesday, Glenmark Pharmaceuticals in partnership with Canadian biotech firm SaNOtize Research has launched Nitric Oxide nasal spray for the treatment of adult patients with Covid-19. The product introduced in India is named under the brand name FabiSpray.
The Mumbai-based drug firm had earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for the Nitric Oxide nasal spray (NONS) as part of the accelerated approval process.
As stated by the company, it has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2.
"As a leading pharmaceutical player, it is important that we are an integral part of India's fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray) and launch it in partnership with SaNOtize. This reaffirms our commitment of providing yet another safe and effective antiviral treatment for COVID-19, and we are confident that it will offer patients a much needed and timely therapy option," said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd.
